Swami Padmanabhan Iyer - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Swami Padmanabhan Iyer

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Expert Review of Hematology|July 12, 2012

Bridging the gap in hematological malignanciesSimrit Parmar, Swami Padmanabhan Iyer

Cancer Chemotherapy and Pharmacology|October 12, 2012

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumorsJohn Nemunaitis, Alain Mita, Joe Stephenson, et al.

Haematologica|March 15, 2015

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal studyAnders Österborg, Roxanne C Jewell, Swami Padmanabhan-Iyer, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Expert Review of Hematology|July 12, 2012

Bridging the gap in hematological malignanciesSimrit Parmar, Swami Padmanabhan Iyer

Cancer Chemotherapy and Pharmacology|October 12, 2012

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumorsJohn Nemunaitis, Alain Mita, Joe Stephenson, et al.

Haematologica|March 15, 2015

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal studyAnders Österborg, Roxanne C Jewell, Swami Padmanabhan-Iyer, et al.

Pageof 1